BioMaxima

BioMaxima Long-term Debt

The Long-Term Debt of BioMaxima (BMX.WA) as of Oct 16, 2026 is 6.48 M PLN. In the previous year, Long-Term Debt was 5.24 M PLN — a change of 23.63% (higher).

Long-term Debt

6.48 MPLN

YoY

23.63%

Last updated:

Long-Term Debt of BioMaxima is 2025 6.48 M PLN. Long-Term Debt of BioMaxima was 2024 5.24 M PLN. It decreases by 23.63% higher compared to the previous year.

The BioMaxima Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
7.44 M PLN
Jan 1, 2019
6.18 M PLN
Jan 1, 2020
7.09 M PLN
Jan 1, 2021
8.02 M PLN
Jan 1, 2022
3.86 M PLN
Jan 1, 2023
8.61 M PLN
Jan 1, 2024
5.24 M PLN
Jan 1, 2025
6.48 M PLN
The BioMaxima Long-term Debt history
YEARLong-term DebtYoY
6.48 MPLN+23.63%
5.24 MPLN-39.09%
8.61 MPLN+122.95%
3.86 MPLN-51.86%
8.02 MPLN+13.09%
7.09 MPLN+14.83%
6.18 MPLN-17.03%
7.44 MPLN+382.98%
1.54 MPLN+18.42%
1.30 MPLN-64.20%
3.64 MPLN—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioMaxima Stock analysis

What does BioMaxima do? BioMaxima SA is a company based in Lublin, Poland, operating within the Health Care sector, specifically in the Health Care industry. The company went public via an IPO on June 8, 2010, and is listed under the ticker BMX.WA with ISIN PLBIOMX00015. BioMaxima SA specializes in biotechnology and laboratory diagnostics, manufacturing and distributing reagents and equipment for laboratory diagnosis. The company produces in vitro diagnostic reagents and offers a range of products including diagnostic reagents and analyzers for clinical biochemistry, rapid tests and readers for detecting infectious diseases, cancer markers, cardiac markers, and drugs of abuse, urine analysis systems, hematology analyzers and reagents, ion-selective analyzers and reagents, reagents and immunological analyzers for cardiac markers, glucometers, and analyzers for gasometric and critical blood parameters tests. BioMaxima SA supplies hospitals and laboratories across Poland, Lithuania, Latvia, Romania, and France. The company merged with its wholly owned subsidiary Cebo Sp z o o on March 20, 2014. The company's website is https://biomaxima.com/. BioMaxima is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioMaxima stock

Long-Term Debt of BioMaxima is 6.48 M PLN in 2025.

Long-Term Debt of BioMaxima changed from 5.24 M PLN to 6.48 M PLN, representing a 23.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt BioMaxima since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's PLN is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's BioMaxima historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — BioMaxima

All Key Metrics — BioMaxima